a control arm, and most of the trials of favilavir were<br/>based on a small sample size. For more reliable assess-<br/>ment of the effectiveness of favilavir for treating<br/>COVID-19, large-scale randomized controlled trials<br/>should be conducted.<br/><br/>Lopinavir and ritonavir were reported to have<br/>in vitro inhibitory activity against SARS-CoV and<br/>MERS-CoV“™!'’, Alone, the combination of lopinavir